Kaiser Permanente research exhibits 3 doses of Moderna COVID-19 vaccine extremely efficient in opposition to hospitalization from omicron or delta.
New Kaiser Permanente analysis revealed on February 21, 2022, in Nature Drugs exhibits that whereas Moderna COVID-19 vaccine safety is robust in opposition to coronavirus an infection by the delta variant, it isn't as sturdy in opposition to an infection from the omicron variant.
Three doses of the Moderna COVID-19 vaccine had been extremely efficient in opposition to hospitalization brought on by an infection from both the omicron or delta variant.
This research was performed inside the racially and ethnically various membership of Kaiser Permanente in Southern California utilizing specimens collected between December 6 and December 31, 2021.
It included 26,683 sufferers who examined constructive for COVID-19, 16% of whom had delta infections and 84% of whom had omicron infections, and greater than 67,000 people who examined adverse as a comparability group. Specimens had been primarily collected utilizing nasopharyngeal or oropharyngeal swabs for folks with COVID-19 signs and saliva for individuals who didn't have signs.
- Two doses of the Moderna COVID-19 vaccine had been 44% efficient in opposition to omicron an infection inside 3 months after vaccination, and effectiveness rapidly declined thereafter.
- Three doses of the Moderna COVID-19 vaccine inside 2 months of vaccination had been 94% efficient in opposition to delta an infection and 72% efficient in opposition to omicron an infection.
- For individuals who had compromised immune methods, 3-dose effectiveness in opposition to omicron an infection was decrease at 29%.
- The three-dose effectiveness in opposition to hospitalization with delta or with omicron was above 99%.
“Our outcomes recommend that third doses could also be wanted before 6 months after the second dose of the Moderna COVID-19 vaccine to guard in opposition to omicron an infection,” mentioned Hung Fu Tseng, PhD, a researcher with the Kaiser Permanente Southern California Division of Analysis & Analysis and a school member of Kaiser Permanente Bernard J. Tyson Faculty of Drugs, each situated in Pasadena, Calif. “And that 3 doses could also be insufficient to guard people who find themselves immunocompromised from omicron an infection.”
He added: “Reassuringly, 3 doses present sturdy safety in opposition to COVID-19 hospitalization on account of both the omicron or delta variant.”
Reference: “Effectiveness of mRNA-1273 in opposition to SARS-CoV-2 Omicron and Delta variants” by Hung Fu Tseng, Bradley Okay. Ackerson, Yi Luo, Lina S. Sy, Carla A. Talarico, Yun Tian, Katia J. Bruxvoort, Julia E. Tubert, Ana Florea, Jennifer H. Ku, Gina S. Lee, Quickly Kyu Choi, Harpreet S. Takhar, Michael Aragones and Lei Qian, 21 February 2022, Nature Drugs.
DOI: 10.1038/s41591-022-01753-y
Post a Comment